01 Aug 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Shanghai Pharmaceuticals has entered into a strategic framework cooperation agreement with Secondary Military Medical University (SMMU) to form Shanghai Pharmaceuticals Translational Medicine Alliance to develop translational medicine in China.
It is expected that through this research strategic cooperation, Shanghai Pharmaceuticals can draw on the integrated resources combining translational medicine, pharmaceutical research, clinical and affiliated hospital of SMMU, to enhance R&D efficiency and accelerate new product launch in the market.
Meanwhile, SMMU can make use of Shanghai Pharmaceuticals' sufficient experience in the research and development of drugs, its solid industrial foundation and extensive sales network to accelerate the transformation of scientific research and launch new drugs into the market to meet clinical needs. Both sides will give full play to their respective advantages, expand the depth of diversified cooperation and achieve win-win situation in the future.
The agreement is funded by Shanghai Pharmaceuticals to support the development of major innovative health products that possess a certain research foundation, with potential protection of intellectual property rights and developmental feasibility, which are undertaken by the professional team at the SMMU for the joint alliance of translational medicine can fully exercise the advantages of Shanghai Pharmaceuticals as well as the University's to further promote the cooperation between the military and civilians, and R&D on major innovative products, so as to accelerate the transformation of scientific research outcomes.
Upon the new management team's taking office, Shanghai Pharmaceuticals continues to adhere to its trademark of scientific and technological innovation, striving to maintain an open R&D model with an emphasis on translational medicine applications through collecting social innovative resources, exploring the integrative model of "Production, Academy and Research" and forming long term partnership with financially strong research institutes and universities.
Shanghai Pharmaceuticals has established innovative R&D collaboration with many distinctive institutes such as Shanghai Institute of Materia Medica, China Pharmaceutical University, Shenyang Pharmaceutical University, Zhejian University and Shanghai Jiao Tong University, with a total amount reached over $32.63 million (RMB 200 million).